A Study of AK130 in Combination With AK112 for the Treatment of Advanced Pancreatic Cancer

This is an open-label, multi-center phase II clinical study consisting of two parts: Part I: To evaluate the safety and efficacy of AK130 combined with AK112 in advanced pancreatic cancer. Part II: To evaluate the safety and efficacy of AK112, either as monotherapy or in combination with AK130, in advanced pancreatic cancer.

Trial Details

NCT ID
NCT07114315
Phase
PHASE2
Sponsor
Akeso
Status
RECRUITING
Cancer Type
Pancreatic Cancer
Interventions
  • AK112
  • AK130
Locations (sample)
  • Shanghai, Shanghai Municipality, China|31.22222,121.45806
  • Tianjin, Tianjin Municipality, China|39.14222,117.17667

Key Eligibility Criteria

  • Be able and willing to provide written informed consent.
  • Have a life expectancy of at least 3 months.
  • Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
  • Subjects with histologically or cytologically confirmed advanced/metastatic pancreatic ductal adenocarcinoma (PDAC), who have progressed on ≤2 prio…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Pancreatic Cancer Trials on Trialify →